2024
Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems
Zheng J, Sandhu A, Bhatt A, Collins S, Flint K, Fonarow G, Fudim M, Greene S, Heidenreich P, Lala A, Testani J, Varshney A, Wi R, Ambrosy A. Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Failure 2024, 13: 43-54. PMID: 39269395, DOI: 10.1016/j.jchf.2024.08.004.Peer-Reviewed Original ResearchCommunity-based health systemQuality improvement registryHealth systemGuideline-directed medical therapyGuideline-directed medical therapy useEligible hospitalsImprovement registryNational quality improvement registryElectronic health record dataHealth record dataEvidence-based medicationsHF hospitalizationHeart failurePostdischarge strategiesHFrEF patientsFailure hospitalizationMedical therapyCommunity-BasedAngiotensin receptor-neprilysin inhibitorSodium-glucose cotransporter 2 inhibitorsInpatient useRecord dataRenin-angiotensin system inhibitorsMineralocorticoid receptor antagonistsWorsening Renal Function
2023
The Presence Of Clinical COPD Predicts Mortality In Heart Failure Patient Population
Adeel M, Wakefield D, Soucier R, ZuWallack R, Tabtabai S. The Presence Of Clinical COPD Predicts Mortality In Heart Failure Patient Population. Journal Of Cardiac Failure 2023, 29: 643. DOI: 10.1016/j.cardfail.2022.10.237.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseHFpEF patientsHFrEF patientsHeart failurePrognostic impact of chronic obstructive pulmonary diseaseMedian LOSDiagnosis groupsHF typePresence of chronic obstructive pulmonary diseaseClinical diagnosis of chronic obstructive pulmonary diseaseConcurrent chronic obstructive pulmonary diseaseKaplan-Meier survival curvesComorbid chronic obstructive pulmonary diseaseDiagnosis of chronic obstructive pulmonary diseaseHeart failure patient populationCalcium channel blockersCox regression analysisClinical chronic obstructive pulmonary diseaseIn-Hospital MortalityChronic obstructive pulmonary disease diagnosisDiagnosis of HFYears of ageImpact of chronic obstructive pulmonary diseaseObstructive pulmonary diseasePrognostic impact
2022
Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model
Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.Peer-Reviewed Original ResearchAtrial fibrillationHeart failureRisk scoreEjection fractionHistory of AFRisk/benefit profileBackground Heart failureCardio-embolic strokeDAPA-HF trialModern pharmacological therapyProphylactic anticoagulant therapyRisk/benefit balanceReduced ejection fractionRisk of strokeIdentification of patientsInsulin-treated diabetesProbability of strokePatient-level dataSimple risk modelStroke prediction modelsHFrEF patientsProphylactic anticoagulationHF patientsNT-proBNPPARADIGM-HFConventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials
Shoji S, Kohsaka S, Shiraishi Y, Kohno T, Sawano M, Ikemura N, Niimi N, Nagatomo Y, Tanaka T, Takei M, Ono T, Sakamoto M, Nakano S, Nakamura I, Inoue S, Fukuda K, Yoshikawa T. Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal Of Cardiology 2022, 359: 76-83. PMID: 35421518, DOI: 10.1016/j.ijcard.2022.04.020.Peer-Reviewed Original ResearchConceptsConventional medical therapyHF readmission ratesMedical therapy useMedical therapyLong-term outcomesEnrollment criteriaReadmission ratesTherapy useRecent trialsReduced ejection fractionHeart failure patientsHeart failure treatmentUse of BBsShift trialsDAPA-HFHF registryHFrEF patientsMulticenter registryPARADIGM-HFFailure patientsConsecutive patientsEjection fractionPatient subsetsPrescription ratesFailure treatmentEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extent
2020
Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
Akiyama E, Cinotti R, Čerlinskaitė K, Van Aelst LNL, Arrigo M, Placido R, Chouihed T, Girerd N, Zannad F, Rossignol P, Badoz M, Launay J, Gayat E, Cohen‐Solal A, Lam CSP, Testani J, Mullens W, Cotter G, Seronde M, Mebazaa A. Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. ESC Heart Failure 2020, 7: 996-1006. PMID: 32277607, PMCID: PMC7261539, DOI: 10.1002/ehf2.12645.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionTricuspid annular plane systolic excursionNeutrophil Gelatinase-Associated LipocalinVenous pressureAHF patientsHFrEF patientsCardiac chamber dimensionsEchocardiographic parametersDyspnea patientsHeart failureNatriuretic peptidePlasma volumeMid-regional pro-atrial natriuretic peptideAcute heart failure patientsDiastolic Heart Failure StudyAnnular plane systolic excursionPro-atrial natriuretic peptideB-type natriuretic peptideE-wave deceleration timeInferior vena cava diameterAcute heart failureDiastolic heart failureGelatinase-Associated LipocalinGlomerular filtration rateHeart failure patients
2019
Association between systolic ejection time and outcomes in heart failure by ejection fraction
Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, Honarpour N, Velazquez EJ. Association between systolic ejection time and outcomes in heart failure by ejection fraction. European Journal Of Heart Failure 2019, 22: 1174-1182. PMID: 31863532, PMCID: PMC7493053, DOI: 10.1002/ejhf.1659.Peer-Reviewed Original ResearchConceptsSystolic ejection timeEjection fractionHeart failureClinical outcomesVentricular systolic ejection timeOutpatient transthoracic echocardiogramReduced ejection fractionTertiary referral centerMultivariable logistic regressionHFrEF patientsHF patientsReferral centerTransthoracic echocardiogramAmbulatory patientsHF populationEjection timeEligibility criteriaLogistic regressionPatientsOutcomesAssociationHFpEFEchocardiogramEffects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial
Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.Peer-Reviewed Original ResearchPlacebo-controlled trialReduced ejection fractionEffect of dapagliflozinHeart failureFunctional statusSGLT-2iEjection fractionML/min/m2Double-blind placebo-controlled trialCo-primary end pointsDisease-specific health statusHigh-risk patient populationLarge cardiovascular outcome trialsManifest heart failureUrgent HF visitsKey secondary endpointCardiovascular outcome trialsMajority of patientsMin/m2Type 2 diabetesPg/mLExploratory endpointsHF visitsHFrEF patientsSGLT2i dapagliflozinRepresentativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure
Sayeed S, Fudim M, Xu H, Matsouaka R, Heidenreich P, Yancy C, Fonarow G, Velazquez E, Hernandez A, DeVore A. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. Journal Of Cardiac Failure 2019, 25: s151. DOI: 10.1016/j.cardfail.2019.07.436.Peer-Reviewed Original ResearchAcute decompensated heart failurePIONEER-HF trialSacubitril/valsartanHFrEF patientsCause mortalityEjection fractionEligible cohortHeart failureLeft ventricular ejection fractionGWTG-HF registryHF rehospitalization ratesDecompensated heart failureReduced ejection fractionInitial study populationVentricular ejection fractionClinical trial populationsLong-term outcomesDaily clinical practiceTrial eligibility criteriaGWTG-HFHF hospitalizationHospital initiationPIONEER-HFHF readmissionIndex discharge
2018
Validation and Recalibration of Seattle Heart Failure Model in Japanese Acute Heart Failure Patients
Shiraishi Y, Kohsaka S, Nagai T, Goda A, Mizuno A, Nagatomo Y, Sujino Y, Fukuoka R, Sawano M, Kohno T, Fukuda K, Anzai T, Shadman R, Dardas T, Levy W, Yoshikawa T. Validation and Recalibration of Seattle Heart Failure Model in Japanese Acute Heart Failure Patients. Journal Of Cardiac Failure 2018, 25: 561-567. PMID: 30099192, DOI: 10.1016/j.cardfail.2018.07.463.Peer-Reviewed Original ResearchConceptsSeattle Heart Failure ModelHeart failure patientsHF patientsHeart failure modelHFrEF patientsHFpEF patientsEjection fractionFailure patientsAcute heart failure patientsAcute HF patientsConventional clinical variablesJapanese HF patientsReduced ejection fractionPrecise risk stratificationAcute decompensationHeart failureHospital admissionNational CerebralRisk stratificationClinical variablesC-statisticHeart failure databaseModest discriminationPatientsMedical resources
2017
Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival
Akita K, Kohno T, Kohsaka S, Shiraishi Y, Nagatomo Y, Izumi Y, Goda A, Mizuno A, Sawano M, Inohara T, Fukuda K, Yoshikawa T, Investigators W. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. International Journal Of Cardiology 2017, 235: 162-168. PMID: 28259550, DOI: 10.1016/j.ijcard.2017.02.070.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsFemaleHeart FailureHumansJapanMaleMedication Therapy ManagementMiddle AgedNeeds AssessmentOutcome and Process Assessment, Health CarePatient DischargePatient ReadmissionPractice Guidelines as TopicStroke VolumeVentricular Dysfunction, LeftConceptsGuideline-based medical therapyAcute heart failureReduced ejection fractionElderly patientsHeart failureEjection fractionHF readmissionMedical therapyWest Tokyo Heart Failure registryConsecutive acute HF patientsYounger groupAcute HF patientsElderly HFrEF patientsHeart Failure RegistryEvent-free survivalMulti-center registryIdeal therapeutic approachHF rehospitalizationHFrEF patientsHF patientsCurrent useCardiac deathComposite endpointPrescription ratesPoor outcome
2016
Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction
Jaiswal A, Chichra A, Nguyen VQ, Gadiraju TV, Le Jemtel TH. Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction. Current Heart Failure Reports 2016, 13: 30-36. PMID: 26780914, DOI: 10.1007/s11897-016-0278-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic obstructive pulmonary diseaseReduced ejection fractionObstructive pulmonary diseaseBeta blockersCOPD patientsEjection fractionHeart failurePulmonary diseasePrevalence of COPDManagement of patientsEvidence-based therapiesNumber of patientsHFrEF patientsAldosterone antagonistsEarly referralCOPD treatmentCommon symptomsTherapeutic managementClinical conundrumHFrEFPatientsClinical practiceEnzyme inhibitorsAdverse effectsDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply